CROs offering Translational Research with Oligonucleotide

Matching companies

• ADViRNA

  ADViRNA provides oligonucleotide design, synthesis, and screening services with proprietary chemical modifications and conjugation technologies for therapeutic siRNA and ASO development.

• Aliri Bioanalysis

  Bioanalytical CRO specializing in PK/PD, biomarker, and spatial imaging services across discovery through Phase 3 clinical trials, with 20+ years of regulatory expertise.

• Aragen Life Sciences

  Global CRDMO partner offering integrated discovery-to-commercialization services across small molecules and biologics, with 4000+ scientists and R&D/manufacturing campuses in Asia, North America, and Europe.

• Atheln, Inc.

  Atheln provides customized strategic and operational consulting across product development, CMC, nonclinical, clinical, regulatory, and commercial services for pharma, biotech, and medtech clients.

• Axcelead Drug Discovery Partners, Inc.

  Axcelead provides integrated drug discovery research services to pharmaceutical companies, biotech ventures, and academic institutions. Founded in 2017 from Takeda's drug discovery research base, the company offers expertise across small molecules, nucleic acids, antibodies, and multiple therapeutic modalities.

• Cassia, LLC

  Cassia, LLC is a San Diego-based CRO specializing in green chemo-enzymatic synthesis of stable-isotope labeled metabolites, proteins, and nucleic acids, plus LC-MS/MS RNA modification mapping services for discovery and therapeutic development.

• Certara

  Certara transforms drug development with proprietary biosimulation software, predictive modeling, and AI-driven services spanning discovery through commercialization. Serving 2,400+ biopharmaceutical companies and regulatory agencies across 70 countries, Certara's model-informed drug development (MIDD) platform accelerates clinical and regulatory decision-making.

• ChemDiv

  ChemDiv is a fully integrated target-to-clinic CRO headquartered in San Diego, CA, offering drug discovery services including medicinal chemistry, CADD, ADME/DMPK, toxicology, and custom synthesis alongside the industry's largest commercial screening library of 1.6M compounds.

• ChemPartner

  Global preclinical CRO with 20+ years of experience supporting drug discovery through IND submission across small molecules and biologics, with 2,000+ scientists and facilities worldwide.

• Creative Bioarray

  Creative Bioarray provides preclinical research solutions including drug screening, ADME-PK, toxicity studies, and cell-based services across oncology, neurology, cardiovascular, and metabolic therapeutic areas.

• Cyagen Biosciences

  Cyagen provides genetically engineered animal models, custom cell lines, and viral packaging services for preclinical research, with specialized expertise in humanized mice, gene therapy vectors, and disease-specific models across oncology, neurology, and metabolic disorders.

• Pharmaron

  Premier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.

• SoCal Biosciences, Inc.

  San Diego-based bioanalytical CRO specializing in assay development and analysis for mRNA, oligonucleotides, and large molecules across discovery through clinical development phases.

• Syngene International

  Innovation-led CRDMO offering integrated scientific services from early discovery through commercial manufacturing, with cGMP-compliant facilities, 5,200+ scientists, and a new 50,000-liter single-use bioreactor capacity in the U.S.

• TATAA Biocenter

  GLP- and GCLP-compliant molecular CRO specializing in bioanalysis for gene therapy, RNA therapeutics, and advanced modalities, offering qPCR, NGS, and plasma proteomics services since 2001.

• Tigermed

  Leading global CRO providing end-to-end clinical trial services, preclinical development, medical device and IVD trials, regulatory affairs, and real-world evidence studies across 180+ offices serving 4,000+ customers.

• WuXi AppTec

  Global CRDMO platform providing integrated end-to-end contract research, development, and manufacturing services across discovery, preclinical, clinical, and commercial phases for small molecules, peptides, oligonucleotides, and biologics across 30+ countries.